Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN E versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN E versus WYAMYCIN E.
E-MYCIN E vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic